EUCTR2017-002686-21-IT进行中（未招募）1 期
A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients with Duchenne Muscular Dystrophy -
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patient and/or parent or legal guardian must have the ability and be willing to provide written informed consent prior to any study-related procedures.
- •2. Diagnosis of DMD based on clinical phenotype with increased serum creatine kinase.
- •3. Documented mutation in the dystrophin gene associated with DMD
- •that is amenable to exon 51 skipping.
- •4. Ambulatory or non-ambulatory male.
- •5. Age of major or equal to 5 and minor or equal to18 years at randomization
- •tests, study restrictions, and all study procedures.
- •7. Stable pulmonary and cardiac function, documented within the past year, as measured by:
- •a) Reproducible percent predicted forced vital capacity (FVC) major or equal to 50%
- •b) Left ventricular ejection fraction (LVEF) >55% in patients <10 years of age and >45% in patients major or equal to 10 years of age, as measured (and documented) by echocardiogram.
- •8. Sexually mature males must be willing to use contraception for the duration of the study, if the patient is sexually active.
- •9.Patients and caregiver must agree not to post any study-related information on social media.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Clinically significant medical finding on the physical examination other than DMD that, in the judgment of the Investigator will make the patient unsuitable for participation in, and/or unable to complete the study procedures.
- •2.Other prior or ongoing medical conditions including:
- •a)Acute illness within 28 days of Screening visit;
- •b)Abnormal physical findings, other than those associated with musculoskeletal findings attributable to DMD.
- •3.Laboratory abnormality, that, in the Investigator's opinion, could adversely affect the safety of the patient, make it unlikely that the course of treatment or follow up would be completed, or impair the assessment of study results. These include, but are not limited to:
- •a)Renal insufficiency;
- •b)Impaired hepatic function (ALT and AST elevations inconsistent with age and creatine kinase [CK] level, and elevated direct or indirect bilirubin);
- •c)aPTT values above the upper limit of normal (ULN);
- •d)Platelet count 4.Positive hepatitis B surface antigen or hepatitis C antibody test.
- •5.Known to be positive for human immunodeficiency virus (HIV).
- •6.Severe mental retardation and/or behavioral problems that, in the opinion of the Investigator, could prohibit participation in this study.
- •7.Severe cardiomyopathy that, in the opinion of the Investigator, prohibits participation in this study. Cardiomyopathy that is managed by angiotensin-converting enzyme (ACE) inhibitors or beta blockers is acceptable provided the patient meets the LVEF inclusion criteria.
- •8.Need for mechanical or non-invasive ventilation OR anticipated need for mechanical or non-invasive ventilation within the next year, in the opinion of the Investigator.
- •9.Changes in nutritional or herbal supplements or concomitant medications within 1 month prior to Screening visit or plans to modify dose or regimen during the study.
- •10.Currently on anticoagulants or antithrombotics.
- •11.Received prior treatment with drisapersen.
- •12.Received treatment with eteplirsen or ataluren within the past 14 weeks.
- •13.Received any investigational drug within the past 3 months or 5 half-lives, whichever is longer.
- •14.Known hypersensitivity to any oligonucleotide, as demonstrated by a systemic allergic reaction such as changes in pulse, blood pressure, breathing function, etc.
- •15.Parent or legal guardian is directly or indirectly involved in the conduct and administration of this study as an Investigator, sub investigator, study coordinator, or other study staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved directly or indirectly in the study.
研究者
相似试验
进行中（未招募）
1 期
A study to assess the safety and tolerability of different doses of WVE-210201 in patients with Duchenne Muscular DystrophyMedDRA version: 20.0 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2017-002686-21-GBWave Life Sciences Ltd.32
进行中（未招募）
1 期
A study to assess the safety and tolerability of different doses of WVE-210201 in patients with Duchenne Muscular DystrophyMedDRA version: 20.0 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2017-002686-21-BEWave Life Sciences Ltd.32
进行中（未招募）
1 期
A study to assess the safety and tolerability of different doses of WVE-210201 in patients with Duchenne Muscular DystrophyDuchenne Muscular DystrophyEUCTR2017-002686-21-FRWave Life Sciences Ltd.32
进行中（未招募）
1 期
A study to assess the safety and tolerability of different doses of WVE-210201 in patients with Duchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2017-002686-21-NLWave Life Sciences Ltd.36
已完成
不适用
A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients with Duchenne Muscular Dystrophy10028396DMDDuchenne Muscular DystrophyNL-OMON46461Wave Life Sciences Ltd.4